文献速递白血病淋巴瘤

将免疫治疗纳入成人B细胞前体急性淋巴细胞白血病的一线治疗

Incorporation of immunotherapy into frontline treatment for adults with B-cell precursor acute lymphoblastic leukemia.
PubMed 文献 · Blood · 2025-01-01

综述指出成人B细胞前体急性淋巴细胞白血病(BCP-ALL)完全缓解率仍低于儿童且复发风险高,老年患者对强化疗耐受差;将利妥昔单抗加入化疗可改善结局,伊诺妥珠单抗奥唑米星、贝林妥欧单抗和CAR-T细胞已改变复发/难治及MRD阳性缓解的治疗格局,近期研究显示伊诺妥珠单抗和贝林妥欧单抗用于一线联合或不联合多药化疗有前景,随机试验显示贝林妥欧单抗加入化疗可为MRD阴性首次缓解患者带来生存获益并获美国FDA批准用于巩固治疗;本文综述初治BCP-ALL化学免疫治疗策略的演变。

要点

  • 利妥昔单抗加入化疗方案已显示可改善成人BCP-ALL结局。
  • 伊诺妥珠单抗奥唑米星、贝林妥欧单抗和CAR-T细胞已改变复发/难治BCP-ALL治疗。
  • 随机试验显示贝林妥欧单抗加入化疗为MRD阴性首次缓解患者带来生存获益。

核心结论

  • 成人BCP-ALL的化学免疫治疗策略正在演变,免疫治疗剂有望在不增加毒性的情况下改善缓解并减少复发。

研究设计与样本

  • 本文为综述,聚焦初治成人BCP-ALL中化学免疫治疗策略的演变。

主要发现

  • 过去20年成人BCP-ALL完全缓解率改善但仍低于儿科人群,缓解后复发风险仍高。
  • 儿童启发化疗方案改善了青少年和年轻成人的长期结局,但老年患者耐受差且发病率和死亡率更高。
  • 利妥昔单抗(抗CD20单克隆抗体)加入化疗方案已显示改善结局。
  • 伊诺妥珠单抗奥唑米星(抗CD22抗体药物偶联物)、贝林妥欧单抗(CD3/CD19双特异性抗体构建体)和嵌合抗原受体T细胞获批用于复发或难治性疾病,贝林妥欧单抗获批用于可测量残留病(MRD)阳性缓解。
  • 近期伊诺妥珠单抗和贝林妥欧单抗一线联合或不联合多药化疗的研究显示有前景的结果;随机试验显示贝林妥欧单抗加入化疗可为MRD阴性首次缓解患者提供生存获益,并因此获美国FDA额外批准用于巩固治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although complete remission rates in adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) have improved over the last 2 decades, it is still inferior to that of the pediatric population, and once in remission, the risk of relapse is still high. Furthermore, although pediatric-inspired chemotherapy regimens have improved long-term outcomes for adolescents and young adults, these intensive chemotherapy regimens are not well tolerated in older patients and are associated with higher morbidity and mortality. Immunotherapeutic agents offer a potential opportunity to improve response and decrease relapse without increasing toxicity. The incorporation of rituximab (anti-CD20 monoclonal antibody) into chemotherapy regimens has been shown to improve outcomes. The treatment of BCP-ALL in adults has been transformed with the approval of inotuzumab ozogamicin (anti-CD22 antibody-drug conjugate), blinatumomab (CD3/CD19 bispecific antibody construct), and chimeric antigen receptor T cells for relapsed or refractory disease and of blinatumomab for measurable residual disease (MRD)-positive remission. More recently, studies of inotuzumab and blinatumomab have shown promising results when used up front either with or without multiagent chemotherapy. Blinatumomab has also been shown in a randomized trial to provide a survival benefit in patients with MRD-negative first remission when added to chemotherapy, which recently led to its additional US Food and Drug Administration approval for use in consolidation. In this review, we highlight the evolution of chemoimmunotherapy-based treatment approaches in the management of treatment-naïve BCP-ALL.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Badar T, Luger SM, Litzow MR, et al. Incorporation of immunotherapy into frontline treatment for adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2025. PMID: 39236292. doi:10.1182/blood.2023022921

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。